Evaluation of clinical management of gonorrhoea using enhanced surveillance in South East Queensland

被引:3
作者
Field, Emma [1 ]
Heel, Karen [2 ]
Palmer, Cheryn [3 ]
Vally, Hassan [4 ]
Beard, Frank [1 ]
McCall, Brad [2 ,5 ]
机构
[1] Queensland Hlth, Communicable Dis Branch, Div Chief Hlth Officer, Fortitude Valley Bc, Qld 4006, Australia
[2] Queensland Hlth, Brisbane Southside Populat Hlth Unit, Coopers Plains, Qld 4108, Australia
[3] Princess Alexandra Hosp, Infect Management Serv, Woolloongabba, Qld 4102, Australia
[4] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0220, Australia
[5] Univ Queensland, Mayne Med Sch, Ctr Mil & Vet Hlth, Herston, Qld 4006, Australia
关键词
Neisseria gonorrhoeae; screening; treatment; SEXUALLY-TRANSMITTED INFECTIONS; HIV-INFECTION; MEN; SEX;
D O I
10.1071/SH09111
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Gonorrhoea is the second most common notifiable sexually transmissible infection (STI) in Queensland. Notifications have been increasing since 2002. Enhanced surveillance was undertaken in this study in order to evaluate clinical management and add to understanding of the epidemiology of gonorrhoea and in South East Queensland. Methods: Information on clinical management and an enhanced surveillance form were faxed to clinicians who notified gonorrhoea in the Brisbane Southside Population Health Unit area from 2003 to 2008. Ceftriaxone was recommended for treatment of gonorrhoea cases, as was simultaneous treatment for chlamydia, testing for other STIs and management of sexual contacts. Enhanced surveillance focussed on collecting more detailed epidemiological and clinical management information. Results: A total of 909 enhanced surveillance forms were returned (response rate 72.2%). The use of ceftriaxone increased significantly over the study period from 31.3% in 2003 to 68.4% in 2008 (P < 0.05). However, there remained a considerable proportion of cases that did not receive ceftriaxone (31.6% in 2008). Simultaneous treatment for chlamydia was reported for 70.5% of cases and did not increase over the study period. A high proportion of males were not screened for high risk co-infection such as HIV (49.6%) and syphilis (51.7%). Contact tracing was initiated for 76.5% of cases and did not increase during the study period. Conclusions: Continued education of clinicians on treatment guidelines is needed. Screening of other STIs such as HIV in males with gonorrhoea and increasing contact tracing were identified as aspects of clinical management for future improvement. Overall this study provides useful insights into the clinical management of gonorrhoea in South East Queensland.
引用
收藏
页码:448 / 452
页数:5
相关论文
共 10 条
  • [1] *AUSTR GON SURV PR, 2007, COMMUN DIS INTELL, V32, P227
  • [2] Australian Government Department of Health and Aging, 2009, NAT NOT DIS SURV SYS
  • [3] *COMM DIS BRANCH, 2009, QUEENSL HIV AIDS ANN
  • [4] Risk factors for HIV infection among men who have sex with men
    Koblin, BA
    Husnik, MJ
    Colfax, G
    Huang, YJ
    Madison, M
    Mayer, K
    Barresi, PJ
    Coates, TJ
    Chesney, MA
    Buchbinder, S
    [J]. AIDS, 2006, 20 (05) : 731 - 739
  • [5] Audit on the success of partner notification for sexually transmitted infections in the West Midlands
    Manavi, K.
    Bhaduri, S.
    Tariq, A.
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2008, 19 (12) : 856 - 858
  • [6] Contact tracing for sexually transmitted infections in New South Wales, Australia
    McCarthy, Melissa
    Haddow, Lewis J.
    Furner, Virginia
    Mindel, Adrian
    [J]. SEXUAL HEALTH, 2007, 4 (01) : 21 - 25
  • [7] *NAT CTR HIV EP CL, 2007, HIV AIDS VIR HEP SEX
  • [8] *OFF EC STAT RES, 2007, EXP IND EST RES POP
  • [9] High prevalence of gonococcal and chlamydial infection in men who have sex with men with newly diagnosed HIV infection - An opportunity for same-day presumptive treatment
    Scott, Katherine C.
    Philip, Susan
    Ahrens, Katherine
    Kent, Charlotte K.
    Klausner, Jeffrey D.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (01) : 109 - 112
  • [10] Therapeutic Guidelines Limited, 2003, THER GUID ANT VERS 1